HRP20110761T1 - Spojevi za liječenje dislipidemije i njihova upotreba - Google Patents
Spojevi za liječenje dislipidemije i njihova upotreba Download PDFInfo
- Publication number
- HRP20110761T1 HRP20110761T1 HR20110761T HRP20110761T HRP20110761T1 HR P20110761 T1 HRP20110761 T1 HR P20110761T1 HR 20110761 T HR20110761 T HR 20110761T HR P20110761 T HRP20110761 T HR P20110761T HR P20110761 T1 HRP20110761 T1 HR P20110761T1
- Authority
- HR
- Croatia
- Prior art keywords
- methyl
- bistrifluoromethylbenzyl
- tetrazol
- amino
- trifluoromethyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 16
- 208000032928 Dyslipidaemia Diseases 0.000 title claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 title claims 2
- -1 -NR11R12 Chemical group 0.000 claims 33
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 16
- 125000002877 alkyl aryl group Chemical group 0.000 claims 15
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 9
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 7
- 150000002148 esters Chemical class 0.000 claims 7
- ZERZIYSMNUFKBJ-SFHVURJKSA-N (5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylic acid Chemical compound N1=NN(C)N=C1N([C@@H]1C=2C=C(C(=CC=2N(C(O)=O)CCC1)C(F)(F)F)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 ZERZIYSMNUFKBJ-SFHVURJKSA-N 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000004104 aryloxy group Chemical group 0.000 claims 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- KGCXLSZXKWPIOH-FQEVSTJZSA-N (5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-3,4,5,7,8,9-hexahydro-2h-cyclopenta[h][1]benzazepine-1-carboxylic acid Chemical class CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC=4CCCC=4C=C3N(C(O)=O)CCC2)=N1 KGCXLSZXKWPIOH-FQEVSTJZSA-N 0.000 claims 3
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- FKFCLPIIFIDPKI-VWLOTQADSA-N 2-[4-[[(5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]piperidin-1-yl]acetic acid Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1CCN(CC(O)=O)CC1 FKFCLPIIFIDPKI-VWLOTQADSA-N 0.000 claims 2
- BRPWZGZBDZUXCA-UHFFFAOYSA-N 2-[4-[[5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(3-methyl-1,2-oxazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]cyclohexyl]acetic acid Chemical compound O1N=C(C)C=C1N(C1C2=CC(C)=C(C=C2N(CC2CCC(CC(O)=O)CC2)CCC1)C(F)(F)F)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 BRPWZGZBDZUXCA-UHFFFAOYSA-N 0.000 claims 2
- TZVBICPTKXRYME-VWLOTQADSA-N 3-[[(5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]benzoic acid Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1=CC=CC(C(O)=O)=C1 TZVBICPTKXRYME-VWLOTQADSA-N 0.000 claims 2
- UFXCYRLCVZFMNQ-VWLOTQADSA-N 4-[[(5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]benzoic acid Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1=CC=C(C(O)=O)C=C1 UFXCYRLCVZFMNQ-VWLOTQADSA-N 0.000 claims 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- 101100440695 Dictyostelium discoideum corB gene Proteins 0.000 claims 2
- 108010023302 HDL Cholesterol Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000005024 alkenyl aryl group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- WGJBMEKISIWTOU-ZDGMYTEDSA-N (2s)-3-[5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]-2-methylpropanoic acid Chemical compound C12=CC(C)=C(C(F)(F)F)C=C2N(C[C@H](C)C(O)=O)CCCC1N(C1=NN(C)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WGJBMEKISIWTOU-ZDGMYTEDSA-N 0.000 claims 1
- WLIXIBUJEFQJQM-VWLOTQADSA-N (5s)-1-benzyl-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-methyl-n-(2-methyltetrazol-5-yl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1=CC=CC=C1 WLIXIBUJEFQJQM-VWLOTQADSA-N 0.000 claims 1
- WXRLRJMMKLNZCX-MHZLTWQESA-N (5s)-n-[2-(2-aminoethyl)tetrazol-5-yl]-1-benzyl-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2,3,4,5,7,9-hexahydrofuro[3,4-h][1]benzazepin-5-amine Chemical compound NCCN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC=4COCC=4C=C3N(CC=3C=CC=CC=3)CCC2)=N1 WXRLRJMMKLNZCX-MHZLTWQESA-N 0.000 claims 1
- JWRYZTSUCVVUOS-QFIPXVFZSA-N (5s)-n-[2-(2-aminoethyl)tetrazol-5-yl]-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(3,3,3-trifluoropropyl)-2,3,4,5,7,9-hexahydrofuro[3,4-h][1]benzazepin-5-amine Chemical compound NCCN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC=4COCC=4C=C3N(CCC(F)(F)F)CCC2)=N1 JWRYZTSUCVVUOS-QFIPXVFZSA-N 0.000 claims 1
- JVHSSSVASVBZGF-QHCPKHFHSA-N (5s)-n-[2-(2-aminoethyl)tetrazol-5-yl]-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclopropylmethyl)-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(CCN)N=N2)CCN1CC1CC1 JVHSSSVASVBZGF-QHCPKHFHSA-N 0.000 claims 1
- DDXDRIKSOIXVTQ-BQAIUKQQSA-N (5s)-n-[2-(2-aminoethyl)tetrazol-5-yl]-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclopropylmethyl)-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine;hydrochloride Chemical compound Cl.C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(CCN)N=N2)CCN1CC1CC1 DDXDRIKSOIXVTQ-BQAIUKQQSA-N 0.000 claims 1
- GIZOHUJIEKLOJB-QFIPXVFZSA-N (5s)-n-[2-(2-aminoethyl)tetrazol-5-yl]-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-methyl-1-(1,3-thiazol-2-ylmethyl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(CCN)N=N2)CCN1CC1=NC=CS1 GIZOHUJIEKLOJB-QFIPXVFZSA-N 0.000 claims 1
- YMLCJYKZIZJXSA-NDEPHWFRSA-N (5s)-n-[2-(2-aminoethyl)tetrazol-5-yl]-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-methyl-1-(2-phenylmethoxyethyl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(CCN)N=N2)CCN1CCOCC1=CC=CC=C1 YMLCJYKZIZJXSA-NDEPHWFRSA-N 0.000 claims 1
- XPHIEEJLRHUBSX-IBGZPJMESA-N (5s)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1,7-dimethyl-n-(2-methyltetrazol-5-yl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound N1=NN(C)N=C1N([C@H]1CCCN(C2=CC(=C(C)C=C21)C(F)(F)F)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XPHIEEJLRHUBSX-IBGZPJMESA-N 0.000 claims 1
- VIGSQDXGNZMWCB-NDEPHWFRSA-N (5s)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclopentylmethyl)-11-methyl-n-(2-methyltetrazol-5-yl)-2,3,4,5,7,8,9,10-octahydrobenzo[h][1]benzazepin-5-amine Chemical compound C([C@@H](C=1C=C2CCCCC2=C(C2=1)C)N(CC=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)C1=NN(C)N=N1)CCN2CC1CCCC1 VIGSQDXGNZMWCB-NDEPHWFRSA-N 0.000 claims 1
- WYAPCMZWOKMLHV-DEOSSOPVSA-N (5s)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclopentylmethyl)-7-methyl-n-(2-methyltetrazol-5-yl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1CCCC1 WYAPCMZWOKMLHV-DEOSSOPVSA-N 0.000 claims 1
- FIMOBMQLBHUGEN-VWLOTQADSA-N (5s)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclopentylmethyl)-n-(2-methyltetrazol-5-yl)-2,3,4,5,7,9-hexahydrofuro[3,4-h][1]benzazepin-5-amine Chemical compound CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC=4COCC=4C=C3N(CC3CCCC3)CCC2)=N1 FIMOBMQLBHUGEN-VWLOTQADSA-N 0.000 claims 1
- LUEDXMVWKYTHAI-SANMLTNESA-N (5s)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclopentylmethyl)-n-(2-methyltetrazol-5-yl)-3,4,5,7,8,9-hexahydro-2h-cyclopenta[h][1]benzazepin-5-amine Chemical compound CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC=4CCCC=4C=C3N(CC3CCCC3)CCC2)=N1 LUEDXMVWKYTHAI-SANMLTNESA-N 0.000 claims 1
- GFQMOOFXDAULBL-QFIPXVFZSA-N (5s)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclopropylmethyl)-7-methyl-n-(2-methyltetrazol-5-yl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1CC1 GFQMOOFXDAULBL-QFIPXVFZSA-N 0.000 claims 1
- XJVKFWFJXZOJRC-FQEVSTJZSA-N (5s)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-ethyl-7-methyl-n-(2-methyltetrazol-5-yl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound N1=NN(C)N=C1N([C@H]1CCCN(C2=CC(=C(C)C=C21)C(F)(F)F)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XJVKFWFJXZOJRC-FQEVSTJZSA-N 0.000 claims 1
- WZOIUSUTQFCHGW-VWLOTQADSA-N (5s)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7,9-dimethyl-n-(2-methyltetrazol-5-yl)-1-[[4-(2h-tetrazol-5-yl)phenyl]methyl]-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound C([C@@H](C=1C=C(C(=C(C)C=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC(C=C1)=CC=C1C1=NN=NN1 WZOIUSUTQFCHGW-VWLOTQADSA-N 0.000 claims 1
- IYKHUEFRFDFUTI-QFIPXVFZSA-N (5s)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-methyl-1-[(1-methylimidazol-2-yl)methyl]-n-(2-methyltetrazol-5-yl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1=NC=CN1C IYKHUEFRFDFUTI-QFIPXVFZSA-N 0.000 claims 1
- LAUOYVFATJLYDU-NRFANRHFSA-N (5s)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-methyl-n-(2-methyltetrazol-5-yl)-1-(1,3-thiazol-2-ylmethyl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1=NC=CS1 LAUOYVFATJLYDU-NRFANRHFSA-N 0.000 claims 1
- NNGQXKJWPHTALS-IBGZPJMESA-N (5s)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-methyl-n-(2-methyltetrazol-5-yl)-1-(2h-tetrazol-5-ylmethyl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC=1N=NNN=1 NNGQXKJWPHTALS-IBGZPJMESA-N 0.000 claims 1
- PFVYSWIWCUSXDJ-DEOSSOPVSA-N (5s)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-methyl-n-(2-methyltetrazol-5-yl)-1-(piperidin-4-ylmethyl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1CCNCC1 PFVYSWIWCUSXDJ-DEOSSOPVSA-N 0.000 claims 1
- HAZOBLNDKHJLFM-DEOSSOPVSA-N (5s)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-methyl-n-(2-methyltetrazol-5-yl)-1-(pyridin-3-ylmethyl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1=CC=CN=C1 HAZOBLNDKHJLFM-DEOSSOPVSA-N 0.000 claims 1
- WJZVHBFKTYFQLJ-DEOSSOPVSA-N (5s)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-methyl-n-(2-methyltetrazol-5-yl)-1-(pyridin-4-ylmethyl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1=CC=NC=C1 WJZVHBFKTYFQLJ-DEOSSOPVSA-N 0.000 claims 1
- AUZDLAWXAUEWHC-JIDHJSLPSA-N (5s)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-methyl-n-(2-methyltetrazol-5-yl)-1-(pyridin-4-ylmethyl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine;hydrochloride Chemical compound Cl.C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1=CC=NC=C1 AUZDLAWXAUEWHC-JIDHJSLPSA-N 0.000 claims 1
- VYJWGFAYXAFWTL-AKRCKQFNSA-N (5s)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-methyl-n-(2-methyltetrazol-5-yl)-1-(pyrrolidin-2-ylmethyl)-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1CCCN1 VYJWGFAYXAFWTL-AKRCKQFNSA-N 0.000 claims 1
- SRHWQOQEIYHHDU-VWLOTQADSA-N (5s)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-7-methyl-n-(2-methyltetrazol-5-yl)-1-[[4-(2h-tetrazol-5-yl)phenyl]methyl]-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-amine Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC(C=C1)=CC=C1C1=NN=NN1 SRHWQOQEIYHHDU-VWLOTQADSA-N 0.000 claims 1
- CRGOATIHHLWYTC-VWLOTQADSA-N (5s)-n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-n-(2-methyltetrazol-5-yl)-1-(pyridin-4-ylmethyl)-2,3,4,5,7,9-hexahydrofuro[3,4-h][1]benzazepin-5-amine Chemical compound CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC=4COCC=4C=C3N(CC=3C=CN=CC=3)CCC2)=N1 CRGOATIHHLWYTC-VWLOTQADSA-N 0.000 claims 1
- YPCQNWDNTQVBNF-NRFANRHFSA-N 2-[(5s)-5-[[2-(2-aminoethyl)tetrazol-5-yl]-[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]ethanol Chemical compound N1=NN(CCN)N=C1N([C@@H]1C=2C=C(C(=CC=2N(CCO)CCC1)C(F)(F)F)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 YPCQNWDNTQVBNF-NRFANRHFSA-N 0.000 claims 1
- BEIJZIGQSAGXEC-NRFANRHFSA-N 2-[(5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-2,3,4,5,7,9-hexahydrofuro[3,4-h][1]benzazepin-1-yl]ethanol Chemical compound CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC=4COCC=4C=C3N(CCO)CCC2)=N1 BEIJZIGQSAGXEC-NRFANRHFSA-N 0.000 claims 1
- UZVFPEBKIURQPH-NRFANRHFSA-N 2-[(5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-ethyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]ethanol Chemical compound N1=NN(C)N=C1N([C@@H]1C=2C=C(C(=CC=2N(CCO)CCC1)C(F)(F)F)CC)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 UZVFPEBKIURQPH-NRFANRHFSA-N 0.000 claims 1
- OJHQTXXFFZAHEI-IBGZPJMESA-N 2-[(5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]acetic acid Chemical compound N1=NN(C)N=C1N([C@@H]1C=2C=C(C(=CC=2N(CC(O)=O)CCC1)C(F)(F)F)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OJHQTXXFFZAHEI-IBGZPJMESA-N 0.000 claims 1
- SFSZUUNKFVUKGS-FQEVSTJZSA-N 2-[(5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]ethanol Chemical compound N1=NN(C)N=C1N([C@@H]1C=2C=C(C(=CC=2N(CCO)CCC1)C(F)(F)F)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 SFSZUUNKFVUKGS-FQEVSTJZSA-N 0.000 claims 1
- NQUZWBZHYJTRFZ-NRFANRHFSA-N 2-[2-[(5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]ethoxy]acetic acid Chemical compound N1=NN(C)N=C1N([C@@H]1C=2C=C(C(=CC=2N(CCOCC(O)=O)CCC1)C(F)(F)F)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NQUZWBZHYJTRFZ-NRFANRHFSA-N 0.000 claims 1
- DJNZBQFUPNFHIY-IRQSHYTFSA-N 2-[4-[[(5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-2,3,4,5,7,9-hexahydrofuro[3,4-h][1]benzazepin-1-yl]methyl]cyclohexyl]acetic acid Chemical compound CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC=4COCC=4C=C3N(CC3CCC(CC(O)=O)CC3)CCC2)=N1 DJNZBQFUPNFHIY-IRQSHYTFSA-N 0.000 claims 1
- WFDUVYKBQNFEHP-SANMLTNESA-N 2-[4-[[(5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]phenyl]acetic acid Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1=CC=C(CC(O)=O)C=C1 WFDUVYKBQNFEHP-SANMLTNESA-N 0.000 claims 1
- WQZRSLLOECZVHP-UHFFFAOYSA-N 2-[4-[[5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]cyclohexyl]acetic acid Chemical compound C1=2C=C(C(F)(F)F)C(C)=CC=2C(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCCN1CC1CCC(CC(O)=O)CC1 WQZRSLLOECZVHP-UHFFFAOYSA-N 0.000 claims 1
- IFWLEWADLFGEGJ-VWLOTQADSA-N 2-[5-[[3,5-bis(trifluoromethyl)phenyl]methyl-[(5s)-1-(cyclopentylmethyl)-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-5-yl]amino]tetrazol-2-yl]ethanol Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(CCO)N=N2)CCN1CC1CCCC1 IFWLEWADLFGEGJ-VWLOTQADSA-N 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- XIXGBCXDMXBYBU-DEOSSOPVSA-N 4-[(5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]benzoic acid Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1C1=CC=C(C(O)=O)C=C1 XIXGBCXDMXBYBU-DEOSSOPVSA-N 0.000 claims 1
- WIJMQWOWSQFTBB-NRFANRHFSA-N 4-[(5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]butanoic acid Chemical compound N1=NN(C)N=C1N([C@@H]1C=2C=C(C(=CC=2N(CCCC(O)=O)CCC1)C(F)(F)F)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WIJMQWOWSQFTBB-NRFANRHFSA-N 0.000 claims 1
- YEENIBAWVGXMGC-SANMLTNESA-N 4-[[(5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-ethyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]benzoic acid Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)CC)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1=CC=C(C(O)=O)C=C1 YEENIBAWVGXMGC-SANMLTNESA-N 0.000 claims 1
- YFUPRQYCJVAJKB-SANMLTNESA-N 5-[(5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-2,3,4,5,7,8,9,10-octahydrobenzo[h][1]benzazepin-1-yl]-3,3-dimethylpentanoic acid Chemical compound CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC=4CCCCC=4C=C3N(CCC(C)(C)CC(O)=O)CCC2)=N1 YFUPRQYCJVAJKB-SANMLTNESA-N 0.000 claims 1
- BIYYZNPVJCJREK-DEOSSOPVSA-N 5-[(5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-2,3,4,5,7,9-hexahydrofuro[3,4-h][1]benzazepin-1-yl]-3,3-dimethylpentanoic acid Chemical compound CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC=4COCC=4C=C3N(CCC(C)(C)CC(O)=O)CCC2)=N1 BIYYZNPVJCJREK-DEOSSOPVSA-N 0.000 claims 1
- FSFOGTPFHDZVDY-QHCPKHFHSA-N 5-[(5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]-3,3-dimethylpentanoic acid Chemical compound N1=NN(C)N=C1N([C@@H]1C=2C=C(C(=CC=2N(CCC(C)(C)CC(O)=O)CCC1)C(F)(F)F)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 FSFOGTPFHDZVDY-QHCPKHFHSA-N 0.000 claims 1
- QFNSBPIESHLPIE-VWLOTQADSA-N 5-[(5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-[2-(2-hydroxyethyl)tetrazol-5-yl]amino]-2,3,4,5,7,9-hexahydrofuro[3,4-h][1]benzazepin-1-yl]-3,3-dimethylpentanoic acid Chemical compound N1=NN(CCO)N=C1N([C@H]1CCCN(C2=CC=3COCC=3C=C21)CCC(C)(C)CC(O)=O)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 QFNSBPIESHLPIE-VWLOTQADSA-N 0.000 claims 1
- ZDKDDGYIIGDYRT-QHCPKHFHSA-N 5-[[(5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-2,3,4,5,7,9-hexahydrofuro[3,4-h][1]benzazepin-1-yl]methyl]thiophene-2-carboxylic acid Chemical compound CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)[C@@H]2C3=CC=4COCC=4C=C3N(CC=3SC(=CC=3)C(O)=O)CCC2)=N1 ZDKDDGYIIGDYRT-QHCPKHFHSA-N 0.000 claims 1
- NOFMZHKFQDYPSS-QFIPXVFZSA-N 5-[[(5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepin-1-yl]methyl]thiophene-2-carboxylic acid Chemical compound C([C@@H](C=1C=C(C(=CC=11)C(F)(F)F)C)N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2=NN(C)N=N2)CCN1CC1=CC=C(C(O)=O)S1 NOFMZHKFQDYPSS-QFIPXVFZSA-N 0.000 claims 1
- BWDIHHDYBZAECJ-UHFFFAOYSA-N 5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-2,3,4,5,7,8,9,10-octahydrobenzo[h][1]benzazepine-1-carboxylic acid Chemical compound FC(C=1C=C(CN(C2C3=C(N(CCC2)C(=O)O)C=C2CCCCC2=C3)C=2N=NN(N=2)C)C=C(C=1)C(F)(F)F)(F)F BWDIHHDYBZAECJ-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000005025 alkynylaryl group Chemical group 0.000 claims 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000019439 ethyl acetate Nutrition 0.000 claims 1
- 125000004494 ethyl ester group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- LPKMGYHNCFNWCR-UHFFFAOYSA-N n-[[3,5-bis(trifluoromethyl)phenyl]methyl]-1-(cyclopentylmethyl)-n-(2-methyltetrazol-5-yl)-2,3,4,5,7,8,9,10-octahydrobenzo[h][1]benzazepin-5-amine Chemical compound CN1N=NC(N(CC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)C2C3=CC=4CCCCC=4C=C3N(CC3CCCC3)CCC2)=N1 LPKMGYHNCFNWCR-UHFFFAOYSA-N 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- JGYFOQYFSSXJHV-QFIPXVFZSA-N propan-2-yl (5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-8,9-dimethyl-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound N1=NN(C)N=C1N([C@H]1CCCN(C2=C(C)C(C)=CC=C21)C(=O)OC(C)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 JGYFOQYFSSXJHV-QFIPXVFZSA-N 0.000 claims 1
- NQJUOWYPUVKYTM-QHCPKHFHSA-N propan-2-yl (5s)-5-[[3,5-bis(trifluoromethyl)phenyl]methyl-[2-(2-hydroxyethyl)tetrazol-5-yl]amino]-8,9-dimethyl-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound N1=NN(CCO)N=C1N([C@H]1CCCN(C2=C(C)C(C)=CC=C21)C(=O)OC(C)C)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 NQJUOWYPUVKYTM-QHCPKHFHSA-N 0.000 claims 1
- UWWFUIBLXISBCB-UHFFFAOYSA-N propan-2-yl 5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-8-chloro-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound C12=CC=C(Cl)C=C2N(C(=O)OC(C)C)CCCC1N(C1=NN(C)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 UWWFUIBLXISBCB-UHFFFAOYSA-N 0.000 claims 1
- XTMYYLBYBDPRGG-UHFFFAOYSA-N propan-2-yl 5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]-9-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound C12=CC=C(C(F)(F)F)C(C)=C2N(C(=O)OC(C)C)CCCC1N(C1=NN(C)N=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 XTMYYLBYBDPRGG-UHFFFAOYSA-N 0.000 claims 1
- OHBFCIQJIARLEG-UHFFFAOYSA-N propan-2-yl 5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2h-tetrazol-5-yl)amino]-3,4,5,8,9,10-hexahydro-2h-cyclopenta[i][1]benzazepine-1-carboxylate Chemical compound C12=CC=C3CCCC3=C2N(C(=O)OC(C)C)CCCC1N(C1=NNN=N1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OHBFCIQJIARLEG-UHFFFAOYSA-N 0.000 claims 1
- RXZOHYMVEIIJBK-UHFFFAOYSA-N propan-2-yl 5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2h-tetrazol-5-yl)amino]-7-methyl-8-(trifluoromethyl)-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound C12=CC(C)=C(C(F)(F)F)C=C2N(C(=O)OC(C)C)CCCC1N(C=1NN=NN=1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 RXZOHYMVEIIJBK-UHFFFAOYSA-N 0.000 claims 1
- OKOIBAJDFPVHSX-UHFFFAOYSA-N propan-2-yl 5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(2h-tetrazol-5-yl)amino]-8-chloro-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound C12=CC=C(Cl)C=C2N(C(=O)OC(C)C)CCCC1N(C=1NN=NN=1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 OKOIBAJDFPVHSX-UHFFFAOYSA-N 0.000 claims 1
- JNYUKXLOCJSLJF-UHFFFAOYSA-N propan-2-yl 5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(5-methyl-1h-pyrazol-3-yl)amino]-8-chloro-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound C12=CC=C(Cl)C=C2N(C(=O)OC(C)C)CCCC1N(C1=NNC(C)=C1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 JNYUKXLOCJSLJF-UHFFFAOYSA-N 0.000 claims 1
- WQJOJBGYFCMEHK-UHFFFAOYSA-N propan-2-yl 5-[[3,5-bis(trifluoromethyl)phenyl]methyl-(5-methyl-2h-1,2-oxazol-5-yl)amino]-8-chloro-2,3,4,5-tetrahydro-1-benzazepine-1-carboxylate Chemical compound C12=CC=C(Cl)C=C2N(C(=O)OC(C)C)CCCC1N(C1(C)C=CNO1)CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WQJOJBGYFCMEHK-UHFFFAOYSA-N 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Spoj Formule Inaznačen time šton je 0, 1, 2 ili 3; m je 0, 1, 2 ili 3; p je 1 ili 2; q je 0, 1, 2, 3 ili 4; Y je veza, C=O ili S(O)t; gdje t je 0, 1 ili 2; R1 se bira iz skupine koju čine: hidroksi, C1-C6 alkil, aril, C2-C6 alkenil, C1-C6 halogenalkil, C1-C6 alkil-heterociklil, C3-C8 cikloalkil, C1-C6 alkilcikloalkil, C1-C6 alkilaril, heterociklil, C1-C6 hidroksialkil, C1-C6 alkoksi, ariloksi, -OC2-C6 alkenil, -OC1-C6 halogenalkil, -OC1-C6 alkilheterociklil, -OC3-C8 cikloalkil, -OC1-C6 alkilcikloalkil, -NR7R8, -OC1-C6 alkilaril, -O-heterociklil, -OC1-C6 alkilheterociklil, C1-C6 alkil-O-C(O)NR7R8, C1-C6 alkil-NR7C(O)NR7R8 i C0-C6 alkilCOOR11; uz uvjet da R1 nije hidroksi kada Y je S(O)t; te gdje svaka cikloalkilna, arilna i heterociklička skupina je izborno supstituirana s 1 do 3 skupine, koje se neovisno bira između okso, hidroksi, halogena, C1-C6 alkila, C2-C6 alkenila, C2-C6 alkinila, C1-C6 alkoksi, C1-C6 halogenalkila, C1-C6 hidroksialkila, CONR11R12, NR11SO2R12, NR11COR12, C0-C3 alkilNR11R12, C1-C3 alkilCOR11, C0-C6 alkilCOOR11, cijano, C1-C6 alkilcikloalkila, fenila, -OC1-C6 alkilcikloalkila, -OC1-C6 alkilarila, -OC1-C6 alkilheterociklila i C1-C6 alkilarila; svaki R2 je vezan samo na atom ugljika i skupina je koju se neovisno bira iz skupine koju čine: vodik, hidroksi, halogen, okso, C1-C6 alkil, C2-C6 alkenil, C2-C6 alkinil, C1-C6 alkoksi, C1-C6 halogenalkil, CONR11R12, -NR11SO2R12, -NR11COR12, C0-C6 alkilNR11R12, C0-C6 alkilCOR11, C0-C6 alkilCOOR11, cijano, nitro, C0-C6 alkilcikloalkil, fenil, C0-C6 alkilaril, heterociklil, C3-C8 cikloalkil i C1-C6 halogenalkil; te gdje su dvije neovisno odabrane R2 skupine izborno gem-disupstituirane; R3a i R3b se neovisno bira iz skupine koju čine: vodik, halogen, C1-C6 alkil, C2-C6 alkenil, C2-C6 alkinil, C1-C6 alkoksi i C1-C6 halogenalkil; R4 je skupina koju predstavlja formula -NR4aR4b, gdje: R4a je heterociklilna, C1-C6 alkilheterociklilna ili C2-C6 alkenilheterociklilna skupina, gdje je svaka heterociklička skupina izborno supstituirana s 1 do 3 skupine, koje se neovisno bira iz skupine koju čine: okso, hidroksil, halogen, -NR11R12, C1-C6 alkil, C2-C6 alkenil, C0-C6 alkilCN, C1-C6 alkoksi, C1-C6 hidroksialkil, C1-C6 halogenalkil, -OC(O)NR11R12 i C1-C6 alkilNR11R12, gdje je C1-C6 alkilna skupina izborno supstituirana s -OR10 ili C(O)OR10, C0-C6 alkilNO2, C0-C6 alkilNR11SO2R12, C0-C6 alkilC(O)NR11R12, C0-C6 alkilNR11C(O)R12, C0-C6 alkilNR11C(O)OR12, C0-C6 alkilNR11C(O)NR10R12, C0-C6 alkilNR11CHR10CO2R12, C0-C6 alkilC(O)OR11, C0-C6 alkilSO2NR11R12, C0-C6 alkilS(O)tR11, C3-C8 cikloalkilom, C1-C6 alkilcikloalkilom i C0-C6 alkilheterociklilom, gdje je heterocikl u C0-C6 alkilheterociklilnoj skupini izborno supstituiran s halogenom, C1-C6 alkilom, okso, -CO2R11 i -NR11R12; iR4b se bira iz skupine koju čine: C1-C6 alkilaril, C2-C6 alkenilaril, C2-C6 alkinilaril, C1-C6 alkilheterociklil, C2-C6 alkenilheterociklil, C1-C6 alkilcikloalkil, C1-C6 alkil-O-C1-C6 alkilaril, gdje je svaka cikloalkilna, arilna ili he
Claims (14)
1. Spoj Formule I
[image]
naznačen time što
n je 0, 1, 2 ili 3;
m je 0, 1, 2 ili 3;
p je 1 ili 2;
q je 0, 1, 2, 3 ili 4;
Y je veza, C=O ili S(O)t; gdje t je 0, 1 ili 2;
R1 se bira iz skupine koju čine: hidroksi, C1-C6 alkil, aril, C2-C6 alkenil, C1-C6 halogenalkil, C1-C6 alkil-heterociklil, C3-C8 cikloalkil, C1-C6 alkilcikloalkil, C1-C6 alkilaril, heterociklil, C1-C6 hidroksialkil, C1-C6 alkoksi, ariloksi, -OC2-C6 alkenil, -OC1-C6 halogenalkil, -OC1-C6 alkilheterociklil, -OC3-C8 cikloalkil, -OC1-C6 alkilcikloalkil, -NR7R8, -OC1-C6 alkilaril, -O-heterociklil, -OC1-C6 alkilheterociklil, C1-C6 alkil-O-C(O)NR7R8, C1-C6 alkil-NR7C(O)NR7R8 i C0-C6 alkilCOOR11; uz uvjet da R1 nije hidroksi kada Y je S(O)t; te gdje svaka cikloalkilna, arilna i heterociklička skupina je izborno supstituirana s 1 do 3 skupine, koje se neovisno bira između okso, hidroksi, halogena, C1-C6 alkila, C2-C6 alkenila, C2-C6 alkinila, C1-C6 alkoksi, C1-C6 halogenalkila, C1-C6 hidroksialkila, CONR11R12, NR11SO2R12, NR11COR12, C0-C3 alkilNR11R12, C1-C3 alkilCOR11, C0-C6 alkilCOOR11, cijano, C1-C6 alkilcikloalkila, fenila, -OC1-C6 alkilcikloalkila, -OC1-C6 alkilarila, -OC1-C6 alkilheterociklila i C1-C6 alkilarila;
svaki R2 je vezan samo na atom ugljika i skupina je koju se neovisno bira iz skupine koju čine: vodik, hidroksi, halogen, okso, C1-C6 alkil, C2-C6 alkenil, C2-C6 alkinil, C1-C6 alkoksi, C1-C6 halogenalkil, CONR11R12, -NR11SO2R12, -NR11COR12, C0-C6 alkilNR11R12, C0-C6 alkilCOR11, C0-C6 alkilCOOR11, cijano, nitro, C0-C6 alkilcikloalkil, fenil, C0-C6 alkilaril, heterociklil, C3-C8 cikloalkil i C1-C6 halogenalkil; te gdje su dvije neovisno odabrane R2 skupine izborno gem-disupstituirane;
R3a i R3b se neovisno bira iz skupine koju čine: vodik, halogen, C1-C6 alkil, C2-C6 alkenil, C2-C6 alkinil, C1-C6 alkoksi i C1-C6 halogenalkil;
R4 je skupina koju predstavlja formula -NR4aR4b, gdje:
R4a je heterociklilna, C1-C6 alkilheterociklilna ili C2-C6 alkenilheterociklilna skupina, gdje je svaka heterociklička skupina izborno supstituirana s 1 do 3 skupine, koje se neovisno bira iz skupine koju čine: okso, hidroksil, halogen, -NR11R12, C1-C6 alkil, C2-C6 alkenil, C0-C6 alkilCN, C1-C6 alkoksi, C1-C6 hidroksialkil, C1-C6 halogenalkil, -OC(O)NR11R12 i C1-C6 alkilNR11R12, gdje je C1-C6 alkilna skupina izborno supstituirana s -OR10 ili C(O)OR10, C0-C6 alkilNO2, C0-C6 alkilNR11SO2R12, C0-C6 alkilC(O)NR11R12, C0-C6 alkilNR11C(O)R12, C0-C6 alkilNR11C(O)OR12, C0-C6 alkilNR11C(O)NR10R12, C0-C6 alkilNR11CHR10CO2R12, C0-C6 alkilC(O)OR11, C0-C6 alkilSO2NR11R12, C0-C6 alkilS(O)tR11, C3-C8 cikloalkilom, C1-C6 alkilcikloalkilom i C0-C6 alkilheterociklilom, gdje je heterocikl u C0-C6 alkilheterociklilnoj skupini izborno supstituiran s halogenom, C1-C6 alkilom, okso, -CO2R11 i -NR11R12; i
R4b se bira iz skupine koju čine: C1-C6 alkilaril, C2-C6 alkenilaril, C2-C6 alkinilaril, C1-C6 alkilheterociklil, C2-C6 alkenilheterociklil, C1-C6 alkilcikloalkil, C1-C6 alkil-O-C1-C6 alkilaril, gdje je svaka cikloalkilna, arilna ili heterociklička skupina izborno supstituirana s 1-3 skupine, koje se neovisno bira iz skupine koju čine: hidroksi, okso, -SC1-C6 alkil, C1-C6 alkil, C2-C6 alkenil, C2-C6 alkinil, C1-C6 halogenalkil, halogen, C1-C6 alkoksi, ariloksi, C2-C6 alkeniloksi, C1-C6 halogenalkoksialkil, C0-C6 alkilNR11R12, -OC1-C6 alkilaril, nitro, cijano, C1-C6 halogenalkil-alkohol i C1-C6 hidroksialkil;
R5 se bira iz skupine koju čine: vodik, hidroksi, halogen, C1-C6 alkil, C2-C6 alkenil, C2-C6 alkinil, C1-C6 alkoksi, ariloksi, -OC2-C6 alkenil, -OC1-C6 halogenalkil, C1-C6 halogenalkil, C3-C8 cikloalkil, C1-C6 alkilaril, C1-C6 alkilheterociklil, C2-C6 alkenilaril, C2-C6 alkenilheterociklil, aril, heterociklil, cijano, nitro, C0-C6 alkilNR7R8, C0-C6 alkilCOR7, C0-C6 alkilCO2R7, C0-C6 alkilCONR7R8, CONR7SO2R8, -NR7SO2R8, -NR7COR8, -N=CR7R8, -OCONR7R8, -S(O)tR7, -SO2NR7R8, C0-C5CH2OH, -OC1-C6 alkilheterociklil i -OC1-C6 alkilaril, gdje je svaka od alkilne, alkenilne, alkinilne, cikloalkilne, arilne i heterocikličke skupine ili podskupine izborno supstituirana s okso, alkiloksi, ariloksi; te gdje se bilo koje dvije skupine R5 može kombinirati kako bi tvorile izborno supstituirani 5, 6 ili 7-eročlani prsten kondenziran s fenilnim prstenom (A-prsten), na kojeg su vezane, gdje je 5, 6 ili 7-eročlani kondenzirani prsten zasićen, djelomično nezasićen ili posve nezasićen i izborno sadrži 1, 2 ili 3 heteroatoma, koje se neovisno bira između O, N i S;
R6 se neovisno bira iz skupine koju čine: vodik, C1-C6 alkil, C2-C6 alkenil, hidroksi, COR7, C1-C6 alkoksi, ariloksi, -OC2-C6 alkenil, -OC1-C6 halogenalkil, C1-C6 alkilNR7R8, C3-C8 cikloalkil, heterociklil, aril, C1-C6 alkil-O-C(O)NR7R8, C1-C6 alkil-NR7C(O)NR7R8 i C1-C6 alkilcikloalkil;
svakog od R7 i R8 se neovisno bira iz skupine koju čine: vodik, C1-C6 alkil, C2-C6 alkenil, C2-C6 alkinil, -OC1-C6 alkil, C1-C6 halogenalkil, -O-aril, -OC3-C8 cikloalkil, -O-heterociklil, -C1-C6 alkilcikloalkil, -OC1-C6 alkilcikloalkil, -OC1-C6 alkilheterociklil, C1-C6 alkilheterociklil, -O-C1-C6 alkilaril, C3-C8 cikloalkil, heterociklil, aril i C1-C6 alkilaril, gdje je svaka alkilna, cikloalkilna, heterociklička ili arilna skupina izborno supstituirana s 1-3 skupine, koje se neovisno bira između hidroksi, CN, halogena, C1-C6 alkila, C1-C6 alkoksi, C1-C6 halogenalkila i -NR11R12, ili se R7 i R8 kombinira kako bi tvorili heterociklički prsten s dušikom koji sadrži 0, 1 ili 2 dodatna heteroatoma, koje se bira između kisika, dušika i sumpora, te gdje je heterocikl s dušikom izborno supstituiran s okso ili C1-C6 alkilom;
R10, R11 i R12 se neovisno bira iz skupine koju čine vodik, C1-C6 alkil, C2-C6 alkenil, C3-C8 cikloalkil, heterociklil, aril, C1-C6 alkilaril, gdje je svaka alkilna, arilna, cikloalkilna i heterociklička skupina izborno supstituirana s 1-3 skupine, koje se neovisno bira između halogena, C1-C6 alkilheterociklila i C1-C6 halogenalkila, ili se R11 i R12 kombinira kako bi tvorili heterociklički prsten s dušikom, koji može sadržavati 0, 1 ili 2 dodatna heteroatoma, koje se bira između kisika, dušika ili sumpora i izborno je supstituiran s okso, C1-C6 alkilom, COR7 i -SO2R7;
gdje se termin "aril" odnosi na supstituirani ili nesupstituirani aromatski ili heteroaromatski ili heterociklički radikal (taj termin obuhvaća i heteroarilarilne skupine), te gdje termin aril obuhvaća i benzilnu skupinu;
ili njegova farmaceutski prihvatljiva sol, enantiomer, racemat, dijastereomer ili smjesa dijastereomera.
2. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, enantiomer, racemat, dijastereomer ili smjesa dijastereomera, naznačen time što p je 1.
3. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, enantiomer, racemat, dijastereomer ili smjesa dijastereomera, naznačen time što n, m i q su neovisno 0 ili 1.
4. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, enantiomer, racemat, dijastereomer ili smjesa dijastereomera, naznačen time što p je 1, n je 0, Y je C(O), a R1 se bira iz skupine koju čine: hidroksi, C1-C6 alkil, C0-C6 alkilcikloalkil, C0-C6 alkilheterociklil, C1-C6 halogenalkil, C0-C6 alkilaril, -Oaril, -OC1-C6 halogenalkil, -OC1-C6 alkilcikloalkil, -OC3-C8 cikloalkil, -OC1-C6 alkilcikloalkil, -NR7R8, -OC1-C6 alkil, -OC0-C6 alkilaril, -OC3-C8 cikloalkilCO2R11 i -OC1-C6 alkilheterociklil; te gdje je svaki alkil, cikloalkil, aril ili heterociklil izborno supstituiran s 1 ili 2 skupine, koje se bira između halogena, C0-C3 hidroksialkila, C0-C3 alkilNR11R12, C0-C3 alkilCOOH, cijano i C0-C3 alkilC(O)OC1-C3 alkila.
5. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, enantiomer, racemat, dijastereomer ili smjesa dijastereomera, naznačen time što p je 1, n je 0, Y je veza, a R1 se bira iz skupine koju čine: C1-C6 alkil, C0-C6 alkilcikloalkil, C1-C6 alkilheterociklil, C2-C6 halogenalkil, C0-C6 alkilaril, C1-C6 alkilcikloalkilNR7R8, C1-C6 alkilCO2R11, C1-C6 alkilcikloalkilCO2R11, C1-C6 hidroksialkile i C1-C6 alkil NR7R8; te gdje je svaki alkil, cikloalkil, aril ili heterociklil izborno supstituiran s 1 ili 2 skupine, koje se bira između halogena, C0-C3 hidroksialkila, C0-C3 alkilNR11R12, C0-C3 alkilCOOH, -CONH2 i cijano.
6. Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, enantiomer, racemat, dijastereomer ili smjesa dijastereomera, naznačen time što p je 1, R3a i R3b su oba vodici, a R4 je NR4aR4b; gdje R4b je 3,5-bistrifluormetilbenzil, a R4a se bira iz skupine koju čine:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
gdje se svaki R neovisno bira iz skupine koju čine: halogen, C0-C6 hidroksialkil, vodik, C1-C6 alkil, C1-C6 alkoksi, C0-C6 alkilcikloalkil, C0-C6 alkilheterociklil, C1-C6 alkilCN, C1-C6 halogenalkil, C0-C6 alkilNR11R12, C1-C6 alkilC(O)NR11R12 i C1-C6 alkilC(O)OR11.
7. Spoj, naznačen time što ga se bira iz skupine koju čine:
(S)-(3,5-Bistrifluormetilbenzil)(1-ciklopentilmetil-7-metil-8-trifluormetil-2,3,4,5-tetrahidro-1H-benzo[b]azepin-5-il)(2-metil-2H-tetrazol-5-il)amin,
Izopropilni ester 5-[(3,5-bistrifluormetilbenzil)(1H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-karboksilne kiseline,
Etilni ester (S)-5-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-karboksilne kiseline,
Izopropilni ester (S)-5-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-karboksilne kiseline,
tert-Butilni ester (S)-5-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-karboksilne kiseline,
1-Etilpropilni ester (S)-5-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-karboksilne kiseline,
Ciklopentilni ester (S)-5-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-karboksilne kiseline,
1-Etil-2-metilpropilni ester (S)-5-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-karboksilne kiseline,
Tetrahidropiran-4-ilni ester (S)-5-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-karboksilne kiseline,
(S)-2-{5-[(3,5-Bistrifluormetilbenzil)(1-ciklopentilmetil-7-metil-8-trifluormetil-2,3,4,5-tetrahidro-1H-benzo[b]azepin-5-il)amino]tetrazol-2-il}etanol,
(S)-(3,5-Bistrifluormetilbenzil)(1-etil-7-metil-8-trifluormetil-2,3,4,5-tetrahidro-1H-benzo[b]azepin-5-il)(2-metil-2H-tetrazol-5-il)amin,
(4-{5-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-ilmetil}cikloheksil)octena kiselina,
(S)-5-{5-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-il}-3,3-dimetilpentanska kiselina,
(S)-2-{5-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-il}etanol,
Izopropilni ester (±)-9-[(3,5-Bistrifluormetilbenzil)(2H-tetrazol-5-il)amino]-2,2-difluor-6,7,8,9-tetrahidro-1,3-dioksa-5-azaciklohepta[f]inden-5-karboksilne kiseline,
Izopropilni ester (±)-9-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-2,2-difluor-6,7,8,9-tetrahidro-1,3-dioksa-5-azaciklohepta[f]inden-5-karboksilne kiseline,
(±)-Izopropil-5-[(3,5-bistrifluormetilbenzil)(1H-tetrazol-5-il)amino]-8-klor-2,3,4,5-tetrahidrobenzo[b]azepin-1-karboksilat,
(±)-Izopropil-5-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-8-klor-2,3,4,5-tetrahidrobenzo[b]azepin-1-karboksilat,
(±)-Izopropil-6-[(3,5-bistrifluormetilbenzil)(1H-tetrazol-5-il)amino]-2,3,6,7,8,9-heksahidro-1H-10-azaciklohepta[e]inden-10-karboksilat,
Izopropilni ester (±)-9-[(3,5-bistrifluormetilbenzil)(2H-tetrazol-5-il)amino]-2,3,6,7,8,9-heksahidro-1H-5-azaciklohepta[f]inden-5-karboksilne kiseline,
Izopropilni ester (±)-9-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-2,3,6,7,8,9-heksahidro-1H-5-azaciklohepta[f]inden-5-karboksilne kiseline,
(±)-Izopropil-5-[(3,5-bistrifluormetilbenzil)(5-metil-1H-pirazol-3-il)amino]-8-klor-2,3,4,5-tetrahidrobenzo[b]azepin-1-karboksilat,
(±)-Izopropil-5-[(3,5-bistrifluormetilbenzil)(5-metilizoksazol-5-il)amino]-8-klor-2,3,4,5-tetrahidrobenzo[b]azepin-1-karboksilat,
(±)-Izopropil-5-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-9-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-karboksilat,
Izopropilni ester (S)-6-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-4-metil-2,3,6,7,8,9-heksahidro-1H-10-azaciklohepta[e]inden-10-karboksilne kiseline,
(S)-Izopropil-5-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-8,9-dimetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-karboksilat,
(S)-Izopropil-5-{(3,5-Bistrifluormetilbenzil)[2-(2-hidroksietil)-2H-tetrazol-5-il]amino}-8,9-dimetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-karboksilat,
tert-Butilni ester (S)-9-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-2,3,6,7,8,9-heksahidro-1H-5-azaciklohepta[f]inden-5-karboksilne kiseline,
(S)-(3,5-Bistrifluormetilbenzil)(5-ciklopentilmetil-1,2,3,5,6,7,8,9-oktahidro-5-azaciklohepta[f]inden-9-il)(2-metil-2H-tetrazol-5-il)amin,
(S)-(3,5-Bistrifluormetilbenzil)(5-ciklopentilmetil-3,5,6,7,8,9-heksahidro-1H-2-oksa-5-azaciklohepta[f]inden-9-il)(2-metil-2H-tetrazol-5-il)amin,
(S)-5-{9-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-1,3,6,7,8,9-heksahidro-2-oksa-5-azaciklohepta[f]inden-5-il}-3,3-dimetilpentanska kiselina,
(S)-5-(9-{(3,5-Bistrifluormetilbenzil)[2-(2-hidroksietil)-2H-tetrazol-5-il]amino}-1,3,6,7,8,9-heksahidro-2-oksa-5-azaciklohepta[f]inden-5-il)-3,3-dimetilpentanska kiselina,
Izopropilni ester (S)-9-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-1,3,6,7,8,9-heksahidro-2-oksa-5-azaciklohepta[f]inden-5-karboksilne kiseline,
(3,5-Bistrifluormetilbenzil)(1-ciklopentilmetil-2,3,4,5,7,8,9,10-oktahidro-1H-nafto[2,3-b]azepin-5-il)(2-metil-2H-tetrazol-5-il)amin,
Izopropilni ester 5-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-2,3,4,5,7,8,9,10-oktahidro-nafto[2,3-b]azepin-1-karboksilne kiseline,
Izopropilni ester (S)-9-{(3,5-Bistrifluormetilbenzil)[2-(2-hidroksietil)-2H-tetrazol-5-il]amino}-2,3,6,7,8,9-heksahidro-1H-5-azaciklohepta[f]inden-5-karboksilne kiseline,
Izopropilni ester (R)-9-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-2,3,6,7,8,9-heksahidro-1H-5-azaciklohepta[f]inden-5-karboksilne kiseline,
Izopropilni ester (S)-9-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-2,3,6,7,8,9-heksahidro-1H-5-azaciklohepta[f]inden-5-karboksilne kiseline,
Izopropilni ester (S)-6-{(3,5-Bistrifluormetilbenzil)[2-(2-hidroksietil)-2H-tetrazol-5-il]amino}-2,3,6,7,8,9-heksahidro-1H-10-azaciklohepta[e]inden-10-karboksilne kiseline,
Izopropilni ester (S)-6-{(3,5-Bistrifluormetilbenzil)[2-(2-hidroksietil)-2H-tetrazol-5-il]amino}-4-metil-2,3,6,7,8,9-heksahidro-1H-10-azaciklohepta[e]inden-10-karboksilne kiseline,
2-Metoksikarbonil-2-metilpropilni ester (S)-9-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-2,3,6,7,8,9-heksahidro-1H-5-azaciklohepta[f]inden-5-karboksilne kiseline,
2-Karboksi-2-metilpropilni ester (S)-9-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-2,3,6,7,8,9-heksahidro-1H-5-azaciklohepta[f]inden-5-karboksilne kiseline,
(S)-1-{5-[(3,5-Bistrifluormetilbenzil)-2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-il}-3-furan-2-ilmetoksi)propan-2-on,
2-{5-[(3,5-Bistrifluormetilbenzil)-2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-il}-1-feniletanol,
2-{5-[(3,5-Bistrifluormetilbenzil)-2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-il}-2-feniletanol,
Metilni ester (S)-4-{5-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-ilmetil}benzojeve kiseline,
(S)-4-{5-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-ilmetil}benzojeva kiselina,
Metilni ester (S)-3-{5-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-ilmetil}benzojeve kiseline,
(S)-3-{5-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-ilmetil}benzojeva kiselina,
(S)-4-{5-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-il}benzojeva kiselina,
Metilni ester (4-{5-[(3,5-bistrifluormetilbenzil)(3-metilizoksazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-ilmetil}cikloheksil)octene kiseline,
(4-{5-[(3,5-Bistrifluormetilbenzil)(3-metilizoksazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-ilmetil}cikloheksil)octena kiselina,
(S)-(3,5-Bistrifluormetilbenzil)(7-metil-1-piridin-4-ilmetil-8-trifluormetil-2,3,4,5-tetrahidro-1H-benzo[b]azepin-5-il)(2-metil-2H-tetrazol-5-il)amin,
(S)-(3,5-Bistrifluormetilbenzil)(7-metil-1-piridin-4-ilmetil-8-trifluormetil-2,3,4,5-tetrahidro-1H-benzo[b]azepin-5-il)(2-metil-2H-tetrazol-5-il)amin-hidroklorid,
(S)-(3,5-Bistrifluormetilbenzil)(7-metil-1-piridin-3-ilmetil-8-trifluormetil-2,3,4,5-tetrahidro-1H-benzo[b]azepin-5-il)(2-metil-2H-tetrazol-5-il)amin,
(S)-(3,5-Bistrifluormetilbenzil)(1-ciklopropilmetil-7-metil-8-trifluormetil-2,3,4,5-tetrahidro-1H-benzo[b]azepin-5-il)(2-metil-2H-tetrazol-5-il)amin,
(S)-2-{5-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-etil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-il}etanol,
tert-Butilni ester (S)-(2-{5-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-etil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-il}etil)karbaminske kiseline,
(S)-4-{5-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-etil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-ilmetil}benzojeva kiselina,
(S)5-{9-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-1,3,6,7,8,9-heksahidro-2-oksa-5-azaciklohepta[f]inden-5-ilmetil}tiofen-2-karboksilna kiselina,
(S)-(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)(5-piridin-4-ilmetil-3,5,6,7,8,9-heksahidro-1H-2-oksa-5-azaciklohepta[f]inden-9-il)amin,
(S)-(4-{9-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-1,3,6,7,8,9-heksahidro-2-oksa-5-azaciklohepta[f]inden-5-ilmetil}cikloheksil)octena kiselina,
(S)-2-{9-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-1,3,6,7,8,9-heksahidro-2-oksa-5-azaciklohepta[f]inden-5-il}etanol,
tert-Butilni ester (S)-9-[[2-(2-aminoetil)-2H-tetrazol-5-il](3,5-bistrifluormetilbenzil)amino]-1,3,6,7,8,9-heksahidro-2-oksa-5-azaciklohepta[f]inden-5-karboksilne kiseline,
(S)-[2-(2-Aminoetil)-2H-tetrazol-5-il](5-benzil-3,5,6,7,8,9-heksahidro-1H-2-oksa-5-azaciklohepta[f]inden-9-il)(3,5-bistrifluormetilbenzil)amin,
(S)-[2-(2-Aminoetil)-2H-tetrazol-5-il](3,5-bistrifluormetilbenzil)[5-(3,3,3-trifluorpropil)-3,5,6,7,8,9-heksahidro-1H-2-oksa-5-azaciklohepta[f]inden-9-il]amin,
(S)-5-{5-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-2,3,4,5,7,8,9,10-oktahidronafto[2,3-b]azepin-1-il)-3,3-dimetilpentanska kiselina,
(S)-(3,5-Bistrifluormetilbenzil)(1-ciklopentilmetil-11-metil-2,3,4,5,7,8,9,10-oktahidro-1H-nafto[2,3-b]azepin-5-il)(2-metil-2H-tetrazol-5-il)amin,
(S)-5-{5-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-ilmetil}tiofen-2-karboksilna kiselina,
Etilni ester (S)-5-{5-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-ilmetil}-2-metilpropionske kiseline,
(S)-(3,5-Bistrifluormetilbenzil)(1,7-dimetil-8-trifluormetil-2,3,4,5-tetrahidro-1H-benzo[b]azepin-5-il)(2-metil-2H-tetrazol-5-il)amin,
(S)-(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)(7-metil-1-tiazol-2-ilmetil-8-trifluormetil-2,3,4,5-tetrahidro-1H-benzo[b]azepin-5-il)amin,
(S)-(3,5-Bistrifluormetilbenzil)[7-metil-1-(1-metil-1H-imidazol-2-ilmetil)-8-trifluormetil-2,3,4,5-tetrahidro-1H-benzo[b]azepin-5-il](2-metil-2H-tetrazol-5-il)amin,
(S)-(1-Benzil-7-metil-8-trifluormetil-2,3,4,5-tetrahidro-1H-benzo[b]azepin-5-il)(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amin,
(S)-5-{5-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-ilmetil},
(S)-(4-{5-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-ilmetil}fenil)octena kiselina,
(S)-4-{5-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-il}maslačna kiselina,
(S)-(3,5-Bistrifluormetilbenzil)(7-metil-1-piperidin-4-ilmetil-8-trifluormetil-2,3,4,5-tetrahidro-1H-benzo[b]azepin-5-il)(2-metil-2H-tetrazol-5-il)amin,
Etilni ester (S)-(4-{5-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-ilmetil}piperidin-1-il)octene kiseline,
(S)-(4-{5-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-ilmetil}piperidin-1-il)octena kiselina,
(S)-3-{5-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-il}-2-metilpropionska kiselina,
(S)-(3,5-Bistrifluormetilbenzil)(7-metil-1-pirolidin-2-ilmetil-8-trifluormetil-2,3,4,5-tetrahidro-1H-benzo[b]azepin-5-il)(2-metil-2H-tetrazol-5-il)amin,
(S)-{5-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-il}octena kiselina,
(S)-[2-(2-Aminoetil)-2H-tetrazol-5-il][1-(2-benziloksi-etil)-7-metil-8-trifluormetil-2,3,4,5-tetrahidro-1H-benzo[b]azepin-5-il](3,5-bistrifluormetilbenzil)amin,
(S)-2-{5-[[2-(2-Aminoetil)-2H-tetrazol-5-il](3,5-bistrifluormetilbenzil)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1il}etanol,
tert-Butilni ester (S)-5-[[2-(2-Aminoetil)-2H-tetrazol-5-il](3,5-bistrifluormetilbenzil)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-karboksilne kiseline,
(S)-[2-(2-Aminoetil)-2H-tetrazol-5-il](3,5-bistrifluormetilbenzil)(7-metil-1-tiazol-2-ilmetil-8-trifluormetil-2,3,4,5-tetrahidro-1H-benzo[b]azepin-5-il)amin,
(S)-(2-{5-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-il}etoksi)octena kiselina,
(S)-2-{5-[(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-il}etilni ester octene kiseline,
(S)-(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)[7-metil-1-(2H-tetrazol-5-ilmetil)-8-trifluormetil-2,3,4,5-tetrahidro-1H-benzo[b]azepin-5-il]amin,
2-Aminoetilni ester (S)-5-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-karboksilne kiseline,
2-Karboksi-2-metilpropilni ester (S)-5-[(3,5-bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il)amino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]azepin-1-karboksilne kiseline,
(S)-[2-(2-Aminoetil)-2H-tetrazol-5-il](3,5-bistrifluormetilbenzil)(1-ciklopropilmetil-7-metil-8-trifluormetil-2,3,4,5-tetrahidro-1H-benzo[b]azepin-5-il)amin,
(S)-[2-(2-Aminoetil)-2H-tetrazol-5-il](3,5-bistrifluormetilbenzil)(1-ciklopropilmetil-7-metil-8-trifluormetil-2,3,4,5-tetrahidro-1H-benzo[b]azepin-5-il)amin-hidroklorid,
tert-Butilni ester (S)-5-[(3,5-bistrifluormetilbenzil)fenilamino]-7-metil-8-trifluormetil-2,3,4,5-tetrahidrobenzo[b]zepin-1-karboksilne kiseline,
(S)-(3,5-Bistrifluormetilbenzil)(2-metil-2H-tetrazol-5-il){7-metil-1-[4-(1H-tetrazol-5-il)benzil]-8-trifluormetil-2,3,4,5-tetrahidro-1H-benzo[b]azepin-5-il}amin,
(S)-(3,5-Bistrifluormetilbenzil){7,9-dimetil-1-[4-(1H-tetrazol-5-il)benzil]-8-trifluormetil-2,3,4,5-tetrahidro-1H-benzo[b]azepin-5-il}(2-metil-2H-tetrazol-5-il)amin,
i njihove farmaceutski prihvatljive soli, enantiomeri, racemati, dijastereomeri ili smjese dijastereomera.
8. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentni zahtjeva 1 do 7, ili njegovu farmaceutski prihvatljivu sol, enantiomer, racemat, dijastereomer ili smjesu dijastereomera, kao i najmanje jedno od sljedećeg: podlogu, razrjeđivač i pomoćnu tvar.
9. Spoj u skladu s bilo kojim od patentni zahtjeva 1 do 7 ili njegova farmaceutski prihvatljiva sol, enantiomer, racemat, dijastereomer ili smjesa dijastereomera, naznačen time što je namijenjen upotrebi u terapiji.
10. Spoj u skladu s bilo kojim od patentni zahtjeva 1 do 7 ili njegova farmaceutski prihvatljiva sol, enantiomer, racemat, dijastereomer ili smjesa dijastereomera, naznačen time što je namijenjen upotrebi u liječenju CHD.
11. Spoj u skladu s bilo kojim od patentni zahtjeva 1 do 7 ili njegova farmaceutski prihvatljiva sol, enantiomer, racemat, dijastereomer ili smjesa dijastereomera, naznačen time što je namijenjen upotrebi u liječenju dislipidemije.
12. Spoj u skladu s bilo kojim od patentni zahtjeva 1 do 7 ili njegova farmaceutski prihvatljiva sol, enantiomer, racemat, dijastereomer ili smjesa dijastereomera, naznačen time što je namijenjen upotrebi kod podizanja razine HDL-kolesterol u plazmi.
13. Spoj u skladu s bilo kojim od patentni zahtjeva 1 do 7 ili njegova farmaceutski prihvatljiva sol, enantiomer, racemat, dijastereomer ili smjesa dijastereomera, naznačen time što je namijenjen upotrebi u liječenju patoloških posljedica niskih razina HDL-kolesterola u plazmi kod sisavca.
14. Spoj u skladu s bilo kojim od patentni zahtjeva 1 do 7, ili njegova farmaceutski prihvatljiva sol, enantiomer, racemat, dijastereomer ili smjesa dijastereomera, naznačen time što je namijenjen upotrebi u liječenju ateroskleroze kod sisavca.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58270804P | 2004-06-24 | 2004-06-24 | |
US62724104P | 2004-11-12 | 2004-11-12 | |
US66486205P | 2005-03-24 | 2005-03-24 | |
PCT/US2005/022389 WO2006002342A1 (en) | 2004-06-24 | 2005-06-23 | Compounds and methods for treating dyslipidemia |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20110761T1 true HRP20110761T1 (hr) | 2011-11-30 |
Family
ID=35056992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20110761T HRP20110761T1 (hr) | 2004-06-24 | 2011-10-19 | Spojevi za liječenje dislipidemije i njihova upotreba |
Country Status (27)
Country | Link |
---|---|
US (3) | US20080269284A1 (hr) |
EP (3) | EP1761521A1 (hr) |
JP (2) | JP2008504266A (hr) |
KR (1) | KR20070041452A (hr) |
CN (1) | CN1972932B (hr) |
AT (1) | ATE528304T1 (hr) |
AU (2) | AU2005267436A1 (hr) |
BR (2) | BRPI0512523A (hr) |
CA (2) | CA2570688A1 (hr) |
CR (1) | CR8831A (hr) |
CY (1) | CY1112124T1 (hr) |
DK (1) | DK1761522T3 (hr) |
EA (2) | EA200700119A1 (hr) |
EC (2) | ECSP067095A (hr) |
ES (1) | ES2372291T3 (hr) |
HK (1) | HK1104528A1 (hr) |
HR (1) | HRP20110761T1 (hr) |
IL (2) | IL180277A (hr) |
MA (2) | MA28729B1 (hr) |
MX (2) | MXPA06014716A (hr) |
NO (2) | NO20070468L (hr) |
NZ (1) | NZ550978A (hr) |
PL (1) | PL1761522T3 (hr) |
PT (1) | PT1761522E (hr) |
RS (1) | RS52064B (hr) |
SI (1) | SI1761522T1 (hr) |
WO (2) | WO2006012093A1 (hr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4773969B2 (ja) * | 2003-10-08 | 2011-09-14 | イーライ リリー アンド カンパニー | 脂質代謝異常の治療ための化合物及び方法 |
DK1732933T3 (da) * | 2004-03-26 | 2008-10-27 | Lilly Co Eli | Forobindelser til behandling af dyslipidæmi |
UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
US20080269284A1 (en) | 2004-06-24 | 2008-10-30 | Eli Lilly And Company | Compounds and Methods for Treating Dyslipidemia |
WO2007107843A1 (en) * | 2006-03-22 | 2007-09-27 | Pfizer Products Inc. | Methods of treatment with cetp inhibitors |
TW200808731A (en) | 2006-03-30 | 2008-02-16 | Tanabe Seiyaku Co | A process for preparing tetrahydroquinoline derivatives |
BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
DE102007005045B4 (de) | 2007-01-26 | 2008-12-18 | Sanofi-Aventis | Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2008143127A1 (ja) | 2007-05-17 | 2008-11-27 | Ajinomoto Co., Inc. | 脂質修飾酵素の活性測定法 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
TWI450896B (zh) | 2009-06-30 | 2014-09-01 | Lilly Co Eli | 反式-4-〔〔(5s)-5-〔〔〔3,5-雙(三氟甲基)苯基〕甲基〕(2-甲基-2h-四唑-5-基)胺基〕-2,3,4,5-四氫-7,9-二甲基-1h-1-苯并氮呯-1-基〕甲基〕-環己基羧酸 |
US8785608B2 (en) | 2009-08-26 | 2014-07-22 | Sanofi | Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120058A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
TWI627167B (zh) * | 2011-07-08 | 2018-06-21 | 諾華公司 | 用於高三酸甘油酯個體治療動脈粥狀硬化之方法 |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
PL2860175T3 (pl) * | 2012-06-11 | 2018-07-31 | Tacurion | Sposób wytwarzania związku 4,4,7-trifluoro-1,2,3,4-tetrahydro-5h-1-benzazepinowego i związku pośredniego do jego syntezy |
WO2014012401A1 (zh) * | 2012-07-16 | 2014-01-23 | 上海恒瑞医药有限公司 | 苯并七元杂环类衍生物、其制备方法及其在医药上的应用 |
AU2014381733B2 (en) * | 2014-02-05 | 2020-09-03 | Newamsterdam Pharma B.V. | Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases |
CN103833637B (zh) * | 2014-03-31 | 2016-01-06 | 武汉武药制药有限公司 | 一种制备依塞曲匹(Evacetrapib)中间体的方法 |
LT3307734T (lt) | 2015-06-09 | 2020-05-11 | Abbvie Inc. | Branduolinio receptoriaus moduliatoriai (ror), skirti uždegiminių ir autoimuninių ligų gydymui |
WO2016198908A1 (en) | 2015-06-09 | 2016-12-15 | Abbvie Inc. | Ror nuclear receptor modulators |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2402506A1 (fr) * | 1977-09-09 | 1979-04-06 | Guelennec Emile Le | Cisaille pour la decoupe de ferrailles de grandes dimensions |
GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
HN2000000203A (es) * | 1999-11-30 | 2001-06-13 | Pfizer Prod Inc | Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas. |
CO5271716A1 (es) * | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
RU2265010C2 (ru) * | 2001-04-30 | 2005-11-27 | Пфайзер Продактс Инк. | Промежуточные соединения для ингибиторов cetp и способы их получения |
SK2332004A3 (en) | 2002-08-30 | 2004-12-01 | Japan Tobacco Inc | Dibenzylamine compound and medicinal use thereof |
MXPA05003456A (es) | 2002-10-04 | 2005-07-05 | Millennium Pharm Inc | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias. |
US20060100239A1 (en) | 2003-03-04 | 2006-05-11 | Izuru Nagasaki | Method for producing optically active amines |
US20040204450A1 (en) * | 2003-03-28 | 2004-10-14 | Pfizer Inc | Quinoline and quinoxaline compounds |
JP4773969B2 (ja) | 2003-10-08 | 2011-09-14 | イーライ リリー アンド カンパニー | 脂質代謝異常の治療ための化合物及び方法 |
DK1732933T3 (da) | 2004-03-26 | 2008-10-27 | Lilly Co Eli | Forobindelser til behandling af dyslipidæmi |
UA90269C2 (ru) * | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
US20080269284A1 (en) | 2004-06-24 | 2008-10-30 | Eli Lilly And Company | Compounds and Methods for Treating Dyslipidemia |
US7700774B2 (en) | 2004-12-20 | 2010-04-20 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds and their pharmaceutical compositions |
TWI450896B (zh) * | 2009-06-30 | 2014-09-01 | Lilly Co Eli | 反式-4-〔〔(5s)-5-〔〔〔3,5-雙(三氟甲基)苯基〕甲基〕(2-甲基-2h-四唑-5-基)胺基〕-2,3,4,5-四氫-7,9-二甲基-1h-1-苯并氮呯-1-基〕甲基〕-環己基羧酸 |
-
2005
- 2005-06-22 US US11/570,540 patent/US20080269284A1/en not_active Abandoned
- 2005-06-22 CA CA002570688A patent/CA2570688A1/en not_active Abandoned
- 2005-06-22 BR BRPI0512523-5A patent/BRPI0512523A/pt not_active Application Discontinuation
- 2005-06-22 KR KR1020067027038A patent/KR20070041452A/ko not_active Application Discontinuation
- 2005-06-22 WO PCT/US2005/021789 patent/WO2006012093A1/en active Application Filing
- 2005-06-22 JP JP2007518182A patent/JP2008504266A/ja active Pending
- 2005-06-22 AU AU2005267436A patent/AU2005267436A1/en not_active Abandoned
- 2005-06-22 EA EA200700119A patent/EA200700119A1/ru unknown
- 2005-06-22 EP EP05768995A patent/EP1761521A1/en not_active Withdrawn
- 2005-06-22 MX MXPA06014716A patent/MXPA06014716A/es not_active Application Discontinuation
- 2005-06-23 RS RS20110559A patent/RS52064B/en unknown
- 2005-06-23 AU AU2005258241A patent/AU2005258241B2/en not_active Ceased
- 2005-06-23 AT AT05763328T patent/ATE528304T1/de active
- 2005-06-23 SI SI200531438T patent/SI1761522T1/sl unknown
- 2005-06-23 PL PL05763328T patent/PL1761522T3/pl unknown
- 2005-06-23 NZ NZ550978A patent/NZ550978A/en not_active IP Right Cessation
- 2005-06-23 US US11/570,542 patent/US7786108B2/en not_active Expired - Fee Related
- 2005-06-23 CN CN2005800206855A patent/CN1972932B/zh not_active Expired - Fee Related
- 2005-06-23 JP JP2007518296A patent/JP4836945B2/ja not_active Expired - Fee Related
- 2005-06-23 BR BRPI0512516-2A patent/BRPI0512516A/pt active Search and Examination
- 2005-06-23 EP EP05763328A patent/EP1761522B1/en active Active
- 2005-06-23 PT PT05763328T patent/PT1761522E/pt unknown
- 2005-06-23 DK DK05763328.1T patent/DK1761522T3/da active
- 2005-06-23 EP EP11184746A patent/EP2479175A1/en not_active Withdrawn
- 2005-06-23 MX MXPA06014706A patent/MXPA06014706A/es active IP Right Grant
- 2005-06-23 ES ES05763328T patent/ES2372291T3/es active Active
- 2005-06-23 CA CA2570673A patent/CA2570673C/en not_active Expired - Fee Related
- 2005-06-23 WO PCT/US2005/022389 patent/WO2006002342A1/en active Application Filing
- 2005-06-23 EA EA200700120A patent/EA012585B1/ru not_active IP Right Cessation
-
2006
- 2006-12-19 EC EC2006007095A patent/ECSP067095A/es unknown
- 2006-12-19 EC EC2006007098A patent/ECSP067098A/es unknown
- 2006-12-22 CR CR8831A patent/CR8831A/es unknown
- 2006-12-24 IL IL180277A patent/IL180277A/en not_active IP Right Cessation
- 2006-12-24 IL IL180276A patent/IL180276A0/en unknown
- 2006-12-29 MA MA29595A patent/MA28729B1/fr unknown
- 2006-12-29 MA MA29596A patent/MA28730B1/fr unknown
-
2007
- 2007-01-24 NO NO20070468A patent/NO20070468L/no not_active Application Discontinuation
- 2007-01-24 NO NO20070470A patent/NO20070470L/no not_active Application Discontinuation
- 2007-08-17 HK HK07109002.0A patent/HK1104528A1/xx not_active IP Right Cessation
-
2010
- 2010-04-20 US US12/763,344 patent/US20100204207A1/en not_active Abandoned
-
2011
- 2011-10-19 HR HR20110761T patent/HRP20110761T1/hr unknown
- 2011-11-25 CY CY20111101160T patent/CY1112124T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20110761T1 (hr) | Spojevi za liječenje dislipidemije i njihova upotreba | |
JP2008504277A5 (hr) | ||
RU2470022C2 (ru) | Оксазолидиновые антибиотики | |
HRP20231310T1 (hr) | Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene | |
JP2020530446A5 (hr) | ||
PE20030062A1 (es) | Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas | |
AR049294A1 (es) | DERIVADOS DE QUINAZOLINA; INHIBIDORES DE LA TIROSINA QUINASA DEL RECEPTOR ERBB2; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN; MÉTODOS PARA SU PREPARACIoN Y SU USO COMO MEDICAMENTO PARA EL TRATAMIENTO O PREVENCIoN DE TUMORES SoLIDOS. | |
PE20090884A1 (es) | Compuestos de indol como activadores de glucoquinasa | |
JP2014532660A5 (hr) | ||
RU2012143689A (ru) | Спироциклические соединения и их применение в качестве терапевтических агентов и диагностических зондов | |
RU2006146070A (ru) | Циннамидное соединение | |
RU2004111285A (ru) | Оксазолидинон и/или изоксазолин в качестве антибактериальных средств | |
KR900701780A (ko) | 5'-인돌리닐-5β-아미도메틸옥사졸리딘-2-온, 3-(융합-고리치환된)페닐-5β-아미도메틸옥사졸리딘-2-온 및 3-(질소 치환된)페닐-5β-아미도메틸옥사졸리딘-2-온 | |
PE20090477A1 (es) | Derivados de oxazol como inhibidores de los canales de sodio | |
JP2009502809A5 (hr) | ||
KR890002132A (ko) | 옥사디아졸 무스카린성 효능제 프로드럭 | |
NZ588266A (en) | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists | |
RU2003101970A (ru) | Конденсированные производные азепина и их использование в качестве антидиуретических агентов | |
AR038000A1 (es) | Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento | |
CA2682329A1 (en) | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists | |
HRP20090581T1 (hr) | Spojevi i postupci za liječenje dislipidemije | |
EP1176958A4 (en) | NEW CATECHOLS USED AS ANTIMICROBIAL AGENTS | |
NO883487L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser. | |
RU2348628C2 (ru) | Замещенные циклопропильной группой оксазолидиноновые антибиотики и их производные | |
PT86561A (de) | Neue tricyclische benzimidazole verfahren zu ihrer herstellung und verwendung als arzneimittel |